

Application No.: 10/799,386

Docket No.: 391442005902

REMARKS

Claims 1, 2, 4, 6-7, 10, 15-17, 19-20 and 22-23 are pending after the present amendments. The claims have been amended to correct clerical and typographical errors, and to cancel claims that are directed to non-elected subject matter. Applicants reserve the right to pursue the canceled claims in a divisional application.

Applicants respectfully request entry of the amendments to the specification. The specification has been amended to correct the information concerning related applications, and to correct obvious errors in naming the reactants and intermediates set forth in Example 6. The correct nomenclatures would be readily apparent to those skilled in the art, and the amendments do not constitute new matter.

In particular, the nomenclature error in paragraph [0111] resulted from an incorrect numbering of the oxazole ring system (*i.e.*, 1-(tert-butoxycarbonylaminomethyl) instead of a 2-(tert-butoxycarbonylaminomethyl). (See Exhibit 1). The nomenclature for the resulting product in paragraphs [0112] and [0113] also showed the substituents on the wrong position, resulting in an improper valence. (See Exhibit 2). The errors are obvious based on the structure given for the oxazole reagent on page 36, and the experimental description which provides the resulting product.

Paragraph [0114] describes a general procedure for N-alkylation of the tetrahydroquinoliny secondary amine by reaction with the corresponding mesylate. The general procedure is also described at paragraph [0073]. The incorrect nomenclature for the mesylate reagent again arose from the incorrect nomenclature from the precursor reagent described in paragraphs [00113]. The amendments in paragraphs [0114] and [0115] merely provide the correct nomenclatures for the mesylate of the oxazole reagent shown on page 36, and the resulting alkylated tertiary amine. Thus, the amendments do not add new matter.

Application No.: 10/799,386

Docket No.: 391442005902

CONCLUSION

In view of the above, each of the presently pending claims in this application is believed to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to withdraw the outstanding rejection of the claims and to pass this application to issue. If it is determined that a telephone conference would expedite the prosecution of this application, the Examiner is invited to telephone the undersigned at the number given below.


In the event the U.S. Patent and Trademark office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 391442005902. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: 2/1/06

Respectfully submitted,


By Emily C. Tongco
Emily C. Tongco
Registration No.: 46,473
MORRISON & FOERSTER LLP
12531 High Bluff Drive
Suite 100
San Diego, California 92130-2040
(858) 314-5413

sd-300092




methyl-1-[N-(t-butoxycarbonyl)-aminomethyl]-oxazole-3-carboxylate

Caution: Valence appears to be exceeded




2-(tert-butoxycarbonylamino-methyl)-oxazole-4-carboxylic acid methyl ester

EXHIBIT 1



1-[N-(t-butoxycarbonyl)-aminomethyl]-3-hydroxymethyloxazole

Caution: Valence appears to be exceeded



(4-hydroxymethyl-oxazol-2-ylmethyl)-carbamic acid tert-butyl ester

EXHIBIT 2